The Okayama Lung Cancer Study Group Experience: A Comparison of the Incidence and Pattern of Interstitial Lung Disease during Erlotinib and Gefitinib Treatment in Japanese Patients with Non-Small Cell Lung Cancer
Received Date: May 29, 2023 / Published Date: Jun 29, 2023
Citation: Hotta K (2023) The Okayama Lung Cancer Study Group Experience:A Comparison of the Incidence and Pattern of Interstitial Lung Disease duringErlotinib and Gefitinib Treatment in Japanese Patients with Non-Small Cell LungCancer. Int J Inflam Cancer Integr Ther, 10: 227.
Copyright: © 2023 Hotta K. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.